Meacor
Meacor Inc. is dedicated to developing innovative solutions for heart valve regurgitation, focusing on minimally invasive procedures to improve patient outcomes. Their mission is to address the large unmet clinical need for safer, less invasive treatments for valve diseases, leveraging advanced technology such as cryoadhesion and novel anchoring techniques.
Industries
Nr. of Employees
small (1-50)
Patents
Instrument including a movement sensor for determining the position of an anchoring mechanism
US-9474471-B2
View Details
Instrument including a movement sensor for determining the position of an anchoring mechanism
US-9474471-B2
View DetailsProducts
Investigational catheter-based cryo-anchoring annuloplasty system
An investigational, catheter-delivered system that uses cryoadhesion to anchor devices around the valve annulus and a cinching mechanism to reduce annular diameter in a beating heart procedure; intended as a transcatheter alternative to open surgical annuloplasty.
Investigational catheter-based cryo-anchoring annuloplasty system
An investigational, catheter-delivered system that uses cryoadhesion to anchor devices around the valve annulus and a cinching mechanism to reduce annular diameter in a beating heart procedure; intended as a transcatheter alternative to open surgical annuloplasty.
Services
Engagements with research institutions, accelerator programs, and industry partners to advance preclinical development and commercialization of the device.
Engagements with research institutions, accelerator programs, and industry partners to advance preclinical development and commercialization of the device.
Expertise Areas
- Transcatheter valve repair
- Minimally invasive cardiac device development
- Catheter and steerable sheath design
- Cryoadhesion technology for tissue anchoring
Key Technologies
- Cryoadhesion-based tissue anchoring
- Transcatheter annuloplasty
- Steerable catheter systems
- Low-profile catheter/sheath design (15 Fr class)
News & Updates
Meacor received the first place award at the M2D2 IMPACT Accelerator Pitch-Off for their innovative solution to Mitral valve regurgitation. The program is a 12-week accelerator connecting startups with resources for commercialization.
Received first place for innovative solution to Mitral valve regurgitation at the M2D2 IMPACT accelerator program.
Meacor received the first place award at the M2D2 IMPACT Accelerator Pitch-Off for their innovative solution to Mitral valve regurgitation. The program is a 12-week accelerator connecting startups with resources for commercialization.
Received first place for innovative solution to Mitral valve regurgitation at the M2D2 IMPACT accelerator program.